Tetrahydrocurcumin

Tetrahydrocurcumin at a Glance

Tetrahydrocurcumin, usually abbreviated THC, is the major reductive metabolite of curcumin — the bright-orange pigment of turmeric. When curcumin is eaten, gut bacteria and liver enzymes rapidly add hydrogen across the two double bonds of its central chain, producing this colorless, saturated relative ^{1,2Reference 1Hassaninasab A et al. · 2011Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganismView study →Reference 2Pan MH et al. · 1999AnimalBiotransformation of curcumin through reduction and glucuronidation in miceView study →}.

That single chemical change matters. Compared with curcumin, THC is colorless, more water-soluble, and chemically far more stable — curcumin degrades quickly at the neutral-to-alkaline pH of the gut and blood, whereas THC does not. In many laboratory assays THC is also the stronger antioxidant of the two ^{4,5,6Reference 4Aggarwal BB et al. · 2014Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responsesView study →Reference 5Osawa T et al. · 1995Antioxidative activity of tetrahydrocurcuminoidsView study →Reference 6Somparn P et al. · 2007Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivativesView study →}.

This sets up the compound’s central and genuinely unresolved question: because so little intact curcumin survives absorption, a good share of what people call “curcumin’s effects” after an oral dose may actually be the work of THC and its conjugates circulating in the body ^{2,3Reference 2Pan MH et al. · 1999AnimalBiotransformation of curcumin through reduction and glucuronidation in miceView study →Reference 3Ireson C et al. · 2001AnimalCharacterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivoView study →}. THC is documented as an antioxidant, anti-inflammatory, anti-diabetic/metabolic, neuroprotective and topical skin-brightening agent — but almost entirely in cell and animal studies, and it is important to keep THC-specific findings separate from those of its parent ^{8Reference 8Lai CS et al. · 2020The cancer chemopreventive and therapeutic potential of tetrahydrocurcuminView study →}.

Tetrahydrocurcumin vs. Curcumin

This comparison is the point of the page. THC and curcumin share the same diarylheptanoid skeleton, but the two carbon–carbon double bonds on curcumin’s central heptanoid chain are saturated (hydrogenated) in THC. The consequences run in both directions ^{4Reference 4Aggarwal BB et al. · 2014Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responsesView study →}:

Where THC wins.

• Stability. Curcumin is notoriously unstable, decomposing within minutes at physiological pH. THC lacks that reactive conjugated system and is much more stable, which is one reason it survives in the body as a circulating species ^{3,8Reference 3Ireson C et al. · 2001AnimalCharacterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivoView study →Reference 8Lai CS et al. · 2020The cancer chemopreventive and therapeutic potential of tetrahydrocurcuminView study →}.
• Water solubility & colour. THC is colorless and more water-soluble, making it attractive as a cosmetic and supplement ingredient that will not stain ^{8Reference 8Lai CS et al. · 2020The cancer chemopreventive and therapeutic potential of tetrahydrocurcuminView study →}.
• Antioxidant strength. Because reduction gives it additional labile hydrogens, THC out-performs curcumin as a direct radical scavenger (DPPH, lipid peroxidation) in several head-to-head assays and is a strong inducer of phase-II antioxidant enzymes such as glutathione-S-transferase ^{4,5,6Reference 4Aggarwal BB et al. · 2014Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responsesView study →Reference 5Osawa T et al. · 1995Antioxidative activity of tetrahydrocurcuminoidsView study →Reference 6Somparn P et al. · 2007Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivativesView study →}.

Where curcumin wins. Curcumin’s central α,β-unsaturated β-diketone is a Michael acceptor — a reactive handle it uses to engage many protein targets. THC lacks it, so curcumin remains the more potent agent at several targets, including NF-κB, COX-2 and some viral-entry mechanisms ^{4Reference 4Aggarwal BB et al. · 2014Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responsesView study →}. In one in-vivo comparison curcumin, not THC, more effectively suppressed tumour-promoter-induced reactive oxygen species in leukocytes ^{7Reference 7Nakamura Y et al. · 1998In vitroInhibitory effects of curcumin and tetrahydrocurcuminoids on the tumor promoter-induced reactive oxygen species generation in leukocytes in vitro and in vivoView study →}.

The honest summary is that THC is not simply “better curcumin” — it is a distinct molecule that trades some of curcumin’s target-binding reactivity for greater stability and radical-quenching antioxidant power ^{4Reference 4Aggarwal BB et al. · 2014Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responsesView study →}.

What It's Used For

THC’s evidence is almost entirely preclinical — isolated-molecule work in cell cultures and rodents — with essentially no controlled human trials of the pure compound. Read the signals below with that ceiling in mind.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every row here rests on isolate cell/animal data (no human trials), so treat the bars as relative, not absolute.

01AntioxidantPromising52%Repeated in-vitro/animal assays, often ≥ curcumin ^{4,5,6Reference 4Aggarwal BB et al. · 2014Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responsesView study →Reference 5Osawa T et al. · 1995Antioxidative activity of tetrahydrocurcuminoidsView study →Reference 6Somparn P et al. · 2007Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivativesView study →}

02Anti-Diabetic / MetabolicShaky40%Consistent rat type-2-diabetes series, isolate, ~80 mg/kg ^{9,10Reference 9Murugan P et al. · 2008AnimalEffect of tetrahydrocurcumin on insulin receptor status in type 2 diabetic ratsView study →Reference 10Pari L · 2007AnimalAntihyperlipidemic effect of curcumin and tetrahydrocurcumin in experimental type 2 diabetic ratsView study →}

03Anti-Inflammatory / AnticancerShaky32%Preclinical mechanistic review; weaker than curcumin at NF-κB/COX-2 ^{4,8Reference 4Aggarwal BB et al. · 2014Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responsesView study →Reference 8Lai CS et al. · 2020The cancer chemopreventive and therapeutic potential of tetrahydrocurcuminView study →}

04NeuroprotectiveShaky30%In-vitro neuronal + eye-disease review, isolate ^{11,12Reference 11Park CH et al. · 2019Neuroprotective effects of tetrahydrocurcumin against glutamate-induced oxidative stress in hippocampal HT22 cellsView study →Reference 12Kao YW et al. · 2020Curcumin metabolite tetrahydrocurcumin in the treatment of eye diseasesView study →}

05Skin-Brightening (Topical)Shaky28%Melanoma-cell tyrosinase suppression; mixed in normal melanocytes ^{13,14Reference 13Tang X et al. · 2021Anti-melanogenic mechanism of tetrahydrocurcumin and enhancing its topical delivery efficacy using a lecithin-based nanoemulsionView study →Reference 14Goenka S · 2021Novel chemically modified curcumin (CMC) analogs exhibit anti-melanogenic activity in primary human melanocytesView study →}

Mechanisms

The load-bearing contrast: saturating curcumin’s central double bonds removes the reactive Michael-acceptor handle (so THC is weaker at NF-κB/COX-2 and some kinases) while adding labile hydrogens (so THC is the better radical scavenger and enzyme inducer) ^{4Reference 4Aggarwal BB et al. · 2014Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responsesView study →}.

Pharmacokinetics

THC’s pharmacokinetics are the reason it matters. When curcumin is taken orally it is poorly absorbed and, of the little that enters the body, much is reduced to dihydro- then tetrahydrocurcumin and conjugated to glucuronides by gut microbiota and liver ^{1,2Reference 1Hassaninasab A et al. · 2011Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganismView study →Reference 2Pan MH et al. · 1999AnimalBiotransformation of curcumin through reduction and glucuronidation in miceView study →}. In mice, the reduced metabolites and their glucuronides are major circulating species after a curcumin dose ^{2Reference 2Pan MH et al. · 1999AnimalBiotransformation of curcumin through reduction and glucuronidation in miceView study →}, and human/rat hepatocyte work confirms curcumin is extensively metabolised to these reduced forms ^{3Reference 3Ireson C et al. · 2001AnimalCharacterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivoView study →}. THC is thus both a more stable molecule than curcumin (it does not undergo curcumin’s rapid alkaline degradation) and more water-soluble, which is the basis of the “more bioavailable curcumin” marketing ^{8Reference 8Lai CS et al. · 2020The cancer chemopreventive and therapeutic potential of tetrahydrocurcuminView study →}. THC itself is then further glucuronidated and cleared, so systemic exposure to the free molecule is still limited.

The compound-page caveat: despite this, there is no robust human pharmacokinetic dataset for orally-dosed pure THC — half-life, oral bioavailability and active-metabolite figures for the supplement form are not well characterised, and most PK knowledge is inferred from curcumin-metabolism studies rather than from dosing THC directly.

Clinical Trials

There are no completed controlled human efficacy trials of isolated tetrahydrocurcumin. Its human “use” is as a cosmetic ingredient and as a marketed nutraceutical; the therapeutic evidence base is preclinical (antioxidant, anti-diabetic, neuroprotective, chemopreventive cell/animal work) ^{8,12Reference 8Lai CS et al. · 2020The cancer chemopreventive and therapeutic potential of tetrahydrocurcuminView study →Reference 12Kao YW et al. · 2020Curcumin metabolite tetrahydrocurcumin in the treatment of eye diseasesView study →}. Human data on the reduced metabolite exist mainly as metabolite measurements within curcumin trials, not as trials of THC given on its own ^{2,3Reference 2Pan MH et al. · 1999AnimalBiotransformation of curcumin through reduction and glucuronidation in miceView study →Reference 3Ireson C et al. · 2001AnimalCharacterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivoView study →}.

Last checked: July 2026.

Isolate vs. Plant Studies

THC inverts the usual “isolate vs. whole plant” framing, because it is barely a plant constituent at all. It occurs only in trace amounts in turmeric; the THC that acts in the body is generated from ingested curcumin ^{1,2Reference 1Hassaninasab A et al. · 2011Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganismView study →Reference 2Pan MH et al. · 1999AnimalBiotransformation of curcumin through reduction and glucuronidation in miceView study →}. Every efficacy study cited here uses the isolated (usually synthetic) molecule — the rat diabetes series ^{9,10Reference 9Murugan P et al. · 2008AnimalEffect of tetrahydrocurcumin on insulin receptor status in type 2 diabetic ratsView study →Reference 10Pari L · 2007AnimalAntihyperlipidemic effect of curcumin and tetrahydrocurcumin in experimental type 2 diabetic ratsView study →}, the neuronal and cosmetic-cell work ^{11,13Reference 11Park CH et al. · 2019Neuroprotective effects of tetrahydrocurcumin against glutamate-induced oxidative stress in hippocampal HT22 cellsView study →Reference 13Tang X et al. · 2021Anti-melanogenic mechanism of tetrahydrocurcumin and enhancing its topical delivery efficacy using a lecithin-based nanoemulsionView study →} — so there is no “whole-extract” version of THC’s evidence to weigh against. The relevant transfer caveat runs the other way: findings for turmeric or curcumin extracts cannot be assumed to be THC’s work, and THC’s isolate findings say nothing about eating turmeric. Where THC is genuinely load-bearing is as the metabolite that may mediate part of oral curcumin’s activity — a hypothesis supported by metabolism studies but not yet proven by dosing THC in people ^{2,3,8Reference 2Pan MH et al. · 1999AnimalBiotransformation of curcumin through reduction and glucuronidation in miceView study →Reference 3Ireson C et al. · 2001AnimalCharacterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivoView study →Reference 8Lai CS et al. · 2020The cancer chemopreventive and therapeutic potential of tetrahydrocurcuminView study →}.

Prevalence in Nature

As a natural product THC has almost no independent occurrence story: it is present only in trace amounts in turmeric (Curcuma longa) and is not a meaningful stored constituent of any herb. Its real “abundance” is endogenous and dietary-derived — it forms wherever ingested curcumin meets reducing gut microbiota (notably Escherichia coli strains carrying the NADPH-dependent curcumin/dihydrocurcumin reductase CurA) and hepatic reductases ^{1,2Reference 1Hassaninasab A et al. · 2011Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganismView study →Reference 2Pan MH et al. · 1999AnimalBiotransformation of curcumin through reduction and glucuronidation in miceView study →}. In that sense THC is less a phytochemical than a mammalian–microbial metabolite of a phytochemical, which is why the material sold and studied is manufactured rather than extracted.

Discovery & Synthesis

THC entered the literature not as a plant discovery but as a metabolite: reductive metabolism of curcumin to dihydro- and tetrahydrocurcumin was documented in rodent studies through the late 1970s and confirmed in mice by Pan, Huang and Lin in 1999, who showed curcumin is biotransformed by reduction and then glucuronidation ^{2Reference 2Pan MH et al. · 1999AnimalBiotransformation of curcumin through reduction and glucuronidation in miceView study →}. Its standout property — antioxidant activity often exceeding curcumin’s — was characterised by Osawa and colleagues in 1995 ^{5Reference 5Osawa T et al. · 1995Antioxidative activity of tetrahydrocurcuminoidsView study →}. The specific intestinal-microbial enzyme (CurA) that carries out the two-step NADPH-dependent reduction was identified by Hassaninasab and co-workers in 2011 ^{1Reference 1Hassaninasab A et al. · 2011Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganismView study →}.

Commercial production is by catalytic hydrogenation of curcumin: adding hydrogen across the two double bonds of curcumin’s heptanoid chain yields a colorless, more stable, more water-soluble powder used in cosmetics (skin-brightening) and in “enhanced-bioavailability” curcumin supplements ^{8Reference 8Lai CS et al. · 2020The cancer chemopreventive and therapeutic potential of tetrahydrocurcuminView study →}. So, like several metabolite-derived actives, commercial THC is a made molecule, produced from purified curcumin rather than isolated from the rhizome.

Patents: not yet researched.

Toxicity & Safety

THC carries a low toxicity flag. It is the body’s own detoxification product of curcumin, is well tolerated in the animal studies that used it (including 45-day rat dosing at 80 mg/kg with benefit, not harm) ^{9,10Reference 9Murugan P et al. · 2008AnimalEffect of tetrahydrocurcumin on insulin receptor status in type 2 diabetic ratsView study →Reference 10Pari L · 2007AnimalAntihyperlipidemic effect of curcumin and tetrahydrocurcumin in experimental type 2 diabetic ratsView study →}, and is used in leave-on cosmetics ^{13Reference 13Tang X et al. · 2021Anti-melanogenic mechanism of tetrahydrocurcumin and enhancing its topical delivery efficacy using a lecithin-based nanoemulsionView study →}. The main caveat is not toxicity but absence of human safety characterisation for the isolated supplement.

Safety at a Glance

✅ Low / no toxicity

• Low apparent toxicity. An endogenous curcumin metabolite; well tolerated in rodent studies and used topically in cosmetics.
• More stable, non-staining. Colorless and chemically stable, unlike its rapidly-degrading, strongly-pigmented parent.
• Human safety data are sparse. No controlled human trials of isolated THC characterise long-term safety, and marketed doses are not validated.
• Metabolic-enzyme interactions not characterised. Like curcumin, THC could in principle affect drug-metabolising enzymes/transporters (CYP, UGT, P-gp), but this has not been mapped for THC specifically — assume the curcumin-class caution.

Reproductive/developmental toxicity of isolated THC has not been characterised; any pregnancy or lactation decision belongs on the parent herb or product page, where intake is decided, not on this molecule page.

Dosage

There is no established human dose for tetrahydrocurcumin. The figures that exist are from research and marketing, not from human efficacy trials:

Rodent mg/kg doses do not translate directly to a human intake, and no human trial has tested a THC dose for any outcome. These are doses studied in research and marketed in products, not a personal recommendation.

References

1. Hassaninasab A, Hashimoto Y, Tomita-Yokotani K, Kobayashi M (2011). Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc Natl Acad Sci U S A. https://pubmed.ncbi.nlm.nih.gov/21467222/
2. Pan MH, Huang TM, Lin JK (1999). Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metabolism and Disposition. https://pubmed.ncbi.nlm.nih.gov/10101144/
3. Ireson C, Orr S, Jones DJ, et al. (2001). Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo. Cancer Research. https://pubmed.ncbi.nlm.nih.gov/11221833/
4. Aggarwal BB, Deb L, Prasad S (2014). Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses. Molecules. https://pubmed.ncbi.nlm.nih.gov/25547723/
5. Osawa T, Sugiyama Y, Inayoshi M, Kawakishi S (1995). Antioxidative activity of tetrahydrocurcuminoids. Bioscience, Biotechnology, and Biochemistry. https://pubmed.ncbi.nlm.nih.gov/8520105/
6. Somparn P, Phisalaphong C, Nakornchai S, Unchern S, Morales NP (2007). Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biological & Pharmaceutical Bulletin. https://pubmed.ncbi.nlm.nih.gov/17202663/
7. Nakamura Y, Ohto Y, Murakami A, Osawa T, Ohigashi H (1998). Inhibitory effects of curcumin and tetrahydrocurcuminoids on the tumor promoter-induced reactive oxygen species generation in leukocytes in vitro and in vivo. Japanese Journal of Cancer Research. https://pubmed.ncbi.nlm.nih.gov/9617340/
8. Lai CS, Ho CT, Pan MH (2020). The cancer chemopreventive and therapeutic potential of tetrahydrocurcumin. Biomolecules. https://pubmed.ncbi.nlm.nih.gov/32486019/
9. Murugan P, Pari L, Rao CA (2008). Effect of tetrahydrocurcumin on insulin receptor status in type 2 diabetic rats. Journal of Biosciences. https://pubmed.ncbi.nlm.nih.gov/18376071/
10. Pari L, Murugan P (2007). Antihyperlipidemic effect of curcumin and tetrahydrocurcumin in experimental type 2 diabetic rats. Renal Failure. https://pubmed.ncbi.nlm.nih.gov/17994458/
11. Park CH, Song JH, Kim SN, et al. (2019). Neuroprotective effects of tetrahydrocurcumin against glutamate-induced oxidative stress in hippocampal HT22 cells. Molecules. https://pubmed.ncbi.nlm.nih.gov/31905820/
12. Kao YW, Hsu SK, Chen JY, et al. (2020). Curcumin metabolite tetrahydrocurcumin in the treatment of eye diseases. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/33379248/
13. Tang X, Dong Q, Li J, et al. (2021). Anti-melanogenic mechanism of tetrahydrocurcumin and enhancing its topical delivery efficacy using a lecithin-based nanoemulsion. Pharmaceutics. https://pubmed.ncbi.nlm.nih.gov/34452146/
14. Goenka S, Simon SR (2021). Novel chemically modified curcumin (CMC) analogs exhibit anti-melanogenic activity in primary human melanocytes. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/34205035/

View all 14 references▾